Research ArticleBRAIN
fMRI Biomarker of Early Neuronal Dysfunction in Presymptomatic Huntington’s Disease
Jane S. Paulsen, Janice L. Zimbelman, Sean C. Hinton, Douglas R. Langbehn, Catherine L. Leveroni, Michelle L. Benjamin, Norman C. Reynolds and Stephen M. Rao
American Journal of Neuroradiology November 2004, 25 (10) 1715-1721;
Jane S. Paulsen
Janice L. Zimbelman
Sean C. Hinton
Douglas R. Langbehn
Catherine L. Leveroni
Michelle L. Benjamin
Norman C. Reynolds
References
- ↵The Huntington’s Disease Collaborative Research Group: a novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993;72:971–983
- ↵Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 1985;44:559–577
- ↵Myers RH, Vonsattel JP, Stevens TJ, et al. Clinical and neuropathologic assessment of severity in Huntington’s disease. Neurology 1988;38:341–347
- ↵Wagster MV, Hedreen JC, Peyser CE, Folstein SE, Ross CA. Selective loss of [3H]kainic acid and [3H]AMPA binding in layer VI of frontal cortex in Huntington’s disease. Exp Neurol 1994;127:70–75
- Sotrel A, Paskevich PA, Kiely DK, Bird ED, Williams RS, Myers RH. Morphometric analysis of the prefrontal cortex in Huntington’s disease. Neurology 1991;41:1117–1123
- ↵Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington’s disease. Neurosci Lett 1991;133:257–261
- ↵Campodonico JR, Aylward E, Codori AM, et al. When does Huntington’s disease begin? J Intl Neuropsychol Soc 1998;4:467–473
- ↵Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord 2000;15:552–560
- Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington’s disease. Brain 1999;122:1667–1678
- ↵Paulsen JS, Zhao H, Stout JC, et al. Clinical markers of early disease in persons near onset of Huntington’s disease. Neurology 2001;57:658–662
- ↵Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797–801
- ↵Dedeoglu A, Kubilus JK, Yang L, et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice. J Neurochem 2003;85:1359–1367
- ↵
- ↵Rammsayer TH. Neuropharmacological evidence for different timing mechanisms in humans. Q J Exp Psychol B 1999;52:273–286
- ↵Artieda J, Pastor MA, Lacruz F, Obeso JA. Temporal discrimination is abnormal in Parkinson’s disease. Brain 1992;115:199–210
- ↵O’Boyle DJ, Freeman JS, Cody FW. The accuracy and precision of timing of self-paced, repetitive movements in subjects with Parkinson’s disease. Brain 1996;119:51–70
- ↵Rao SM, Mayer AR, Harrington DL. The evolution of brain activation during temporal processing. Nat Neurosci 2001;4:317–323
- ↵Woodruff-Pak DS, Papka M. Huntington’s disease and eyeblink classical conditioning: normal learning but abnormal timing. J Intl Neuropsychol Soc 1996;2:323–334
- ↵Langbehn DR, Brinkmann RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of age of onset and penetrance for Huntington’s Disease based on CAG length. Clin Genet 2004;65:267–277
- ↵Oldfield RC. The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychologia 1971;9:97–113
- ↵Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202–1210
- ↵Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136–142
- ↵Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996;29:162–173
- ↵Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. New York: Thieme,1988
- ↵Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 2000;10:120–131
- ↵Weeks RA, Ceballos-Baumann A, Piccini P, Boecker H, Harding AE, Brooks DJ. Cortical control of movement in Huntington’s disease: a PET activation study. Brain 1997;120:1569–1578
- ↵Bartenstein P, Weindl A, Spiegel S, et al. Central motor processing in Huntington’s disease: a PET study. Brain 1997;120:1553–1567
- ↵Haslinger B, Erhard P, Kampfe N, et al. Event-related functional magnetic resonance imaging in Parkinson’s disease before and after levodopa. Brain 2001;124:558–570
- ↵Tobin AJ, Signer ER. Huntington’s disease: the challenge for cell biologists. Trends Cell Biol 2000;10:531–536
- ↵Cepeda C, Ariano MA, Calvert CR, et al. NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 2001;66:525–539
- ↵Cherry JA, Thompson BE, Pho V. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. Biochim Biophys Acta 2001;1518:27–35
- ↵Foroud T, Siemers E, Kleindorfer D, et al. Cognitive scores in carriers of Huntington’s disease gene compared to noncarriers. Ann Neurol 1995;37:657–664
- ↵Lawrence AD, Hodges JR, Rosser AE, et al. Evidence for specific cognitive deficits in preclinical Huntington’s disease. Brain 1998;121:1329–1341
- ↵Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington’s disease. Ann Neurol 1992;31:425–430
- Albin RL, Young AB, Penney JB, et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease. N Engl J Med 1990;322:1293–1298
- ↵Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons. Neurology 1994;44:823–828
- ↵Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53:1293–1296
- ↵Harris GJ, Pearlson GD, Peyser CE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington’s disease. Ann Neurol 1992;31:69–75
- ↵Starkstein SE, Brandt J, Bylsma F, Peyser C, Folstein M, Folstein SE. Neuropsychological correlates of brain atrophy in Huntington’s disease: a magnetic resonance imaging study. Neuroradiology 1992;34:487–489
- ↵Campodonico JR, Codori AM, Brandt J. Neuropsychological stability over two years in asymptomatic carriers of the Huntington’s disease mutation. J Neurol Neurosurg Psychiatry 1996;61:621–624
- ↵Riesen JM, Schnider A. Time estimation in Parkinson’s disease: normal long duration estimation despite impaired short duration discrimination. J Neurol 2001;248:27–35
- ↵Harrington DL, Haaland KY, Hermanowicz N. Temporal processing in the basal ganglia. Neuropsychology 1998;12:3–12
In this issue
Advertisement
fMRI Biomarker of Early Neuronal Dysfunction in Presymptomatic Huntington’s Disease
Jane S. Paulsen, Janice L. Zimbelman, Sean C. Hinton, Douglas R. Langbehn, Catherine L. Leveroni, Michelle L. Benjamin, Norman C. Reynolds, Stephen M. Rao
American Journal of Neuroradiology Nov 2004, 25 (10) 1715-1721;
fMRI Biomarker of Early Neuronal Dysfunction in Presymptomatic Huntington’s Disease
Jane S. Paulsen, Janice L. Zimbelman, Sean C. Hinton, Douglas R. Langbehn, Catherine L. Leveroni, Michelle L. Benjamin, Norman C. Reynolds, Stephen M. Rao
American Journal of Neuroradiology Nov 2004, 25 (10) 1715-1721;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Microglia Mediate Early Corticostriatal Synapse Loss and Cognitive Dysfunction in Huntingtons Disease Through Complement-Dependent Mechanisms
- Longitudinal Evaluation of Magnetic Resonance Spectroscopy Metabolites as Biomarkers in Huntingtons Disease
- Attentional compensation in neurodegenerative diseases: the model of premanifest Huntingtons disease mutation carriers
- Functional brain network modeling in sub-acute stroke patients and healthy controls during rest and continuous attentive tracking
- To CRUNCH or not to CRUNCH: Task Difficulty Affects Functional Brain Reorganisation during Visuospatial Working Memory Performance in Premanifest Huntingtons Disease
- Disease-Modification in Huntingtons Disease: Moving Away from a Single-Target Approach
- Frontal cortex BOLD signal changes in premanifest Huntington disease: A possible fMRI biomarker
- Cognitive decline in prodromal Huntington Disease: implications for clinical trials
- Magnetization Transfer Imaging in Premanifest and Manifest Huntington Disease: A 2-Year Follow-Up
- Cognitive domains that predict time to diagnosis in prodromal Huntington disease
- Behavioral and In Vivo Electrophysiological Evidence for Presymptomatic Alteration of Prefrontostriatal Processing in the Transgenic Rat Model for Huntington Disease
- Tapping linked to function and structure in premanifest and symptomatic Huntington disease
- Increased Cognitive Functioning in Symptomatic Huntington's Disease As Revealed by Behavioral and Event-Related Potential Indices of Auditory Sensory Memory and Attention
- Altered Information Processing in the Prefrontal Cortex of Huntington's Disease Mouse Models
- Detection of Huntington's disease decades before diagnosis: the Predict-HD study
- Psychiatric disorders in preclinical Huntington's disease
- Functional connectivity of the prefrontal cortex in Huntington's disease
- fMRI study of episodic memory in relapsing-remitting MS: correlation with T2 lesion volume.
- Saccades in presymptomatic and early stages of Huntington disease
This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.
More in this TOC Section
Similar Articles
Advertisement